Pharma Business Week articles from September 2004

Pharma Business Week archives from September 2004

New breast cancer clinical trial program commences.
September 6, 2004... 2004 SEP 6 - (NewsRx.com & NewsRx.net) -- Two new multicenter studies to evaluate Bioenvision's (BIV) Modrenal (trilostane), in pre- and post-menopausal forms of breast cancer, were announced. The phase II (pre-menopausal) and phase IV...

DOV collaborates to develop and commercialize depression compounds.
September 6, 2004... 2004 SEP 6 - (NewsRx.com & NewsRx.net) -- Merck & Co., Inc., (MRK) and DOV Pharmaceutical, Inc., (DOVP) announced an agreement for the development and commercialization of DOV's triple uptake inhibitors being developed for depression and...

Positive phase III data released on Zimycan.
September 6, 2004... 2004 SEP 6 - (NewsRx.com & NewsRx.net) -- Barrier Therapeutics, Inc., (BTRX) announced that in a phase III clinical study of Candida-associated diaper dermatitis in infants, Zimycan achieved statistical significance versus vehicle for all...

FDA approves OptiClik, new insulin pen system.
September 6, 2004... 2004 SEP 6 - (NewsRx.com & NewsRx.net) -- Aventis Marisol.Peron@Aventis.com Aventis announced that the U.S. Food and Drug Administration (FDA) has approved OptiClik, a new reusable pen for injecting 24-hour LANTUS (insulin glargine [rDNA...

Ophthalmology company files IND for therapeutic RNAi.
September 6, 2004... 2004 SEP 6 - (NewsRx.com & NewsRx.net) -- Acuity Pharmaceuticals has filed an Investigational New Drug application (IND) with the U.S. Food and Drug Administration (FDA) to initiate phase I clinical trials of Cand5, its lead product candidate...

Elite Pharmaceuticals announces end of merger negotiations.
September 6, 2004... 2004 SEP 6 - (NewsRx.com & NewsRx.net) -- Elite Pharmaceuticals, Inc., (ELI) announced that all negotiations with Nostrum Pharmaceuticals, Inc., relating to a proposed merger transaction between the companies have terminated. Nostrum is a...

Patient enrollment completed in phase I/II trial in AIDS.
September 6, 2004... 2004 SEP 6 - (NewsRx.com & NewsRx.net) -- Advanced Viral Research Corp. (ADVR) announced that all 30 patients have been enrolled in its phase I/II clinical trial of AVR118 in patients with AIDS, thereby completing patient enrollment in this...

First patients enter pivotal phase II study of clofarabine.
September 6, 2004... 2004 SEP 6 - (NewsRx.com & NewsRx.net) -- Bioenvision, Ltd., (BIV) has announced that the first adult patients have been dosed on a pivotal European phase II study to evaluate its lead leukemia compound, clofarabine, in the treatment of adults...

Federal report finds rural areas top urban in treatment for painkiller abuse.
September 6, 2004... 2004 SEP 6 - (NewsRx.com & NewsRx.net) -- A new report, "Treatment Admissions in Urban and Rural Areas Involving Abuse of Narcotic Painkillers: 2002 Update," released by the Substance Abuse and Mental Health Services Administration finds rural...

Pharma company announces equity investment in New River Pharmaceuticals.
September 6, 2004... 2004 SEP 6 - (NewsRx.com & NewsRx.net) -- Par Pharmaceutical Companies, Inc., (NYSE:PRX) announced the purchase of 875,000 shares of common stock of New River Pharmaceuticals Inc. (NASDAQ:NRPH) in New River's initial public offering. The...

Researchers find new hope for detecting gene doping.
September 6, 2004... 2004 SEP 6 - (NewsRx.com & NewsRx.net) -- Researchers have discovered a new method for detecting gene doping in the blood, according to new research featured in the August issue of Molecular Therapy. Molecular Therapy is the official...

Biomarker study to identify unique metabolic signatures for ALS.
September 6, 2004... 2004 SEP 6 - (NewsRx.com & NewsRx.net) -- Metabolon, Inc., announced its collaboration with Massachusetts General Hospital on a new biomarker study funded by the National Institute of Neurological Disorders and Stroke (NINDS). Metabolon...

Aranesp receives positive regulatory opinion for extended dosing in Europe.
September 6, 2004... 2004 SEP 6 - (NewsRx.com & NewsRx.net) -- Amgen, Inc., (AMGN) announced that the European Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion to expand the marketing authorization for Aranesp (darbepoetin alfa)...

Snake venom reveals clues about heart drug.
September 6, 2004... 2004 SEP 6 - (NewsRx.com & NewsRx.net) -- With the help of snake venom and sophisticated laboratory testing, scientists believe they've uncovered the reason why a group of new heart medications was doing some patients more harm than good. ...

FDA approves ophthalmic anti-inflammatory/antibiotic combination product.
September 6, 2004... 2004 SEP 6 - (NewsRx.com & NewsRx.net) -- Pharmos Corp.'s (PARS) former marketing partner, Bausch & Lomb, has received from the U.S. Food and Drug Agency (FDA) an approvable letter for ZyLET, the new drug application which was filed by Bausch &...

New over-the-counter pain relieving cream launched.
September 6, 2004... 2004 SEP 6 - (NewsRx.com & NewsRx.net) -- Naturally Vitamins announced the launch of Wobenzym N Creme. Bearing the respected Wobenzym name, this soothing topical pain reliever is an important addition to Naturally's long-established...

Researchers develop a new in vivo atrial fibrillation model in rats.
September 6, 2004... 2004 SEP 6 - (NewsRx.com & NewsRx.net) -- Newly developed rat model of atrial fibrillation (AF) has several characteristics in common with humans. "Nonpharmacological in vivo models of atrial fibrillation (AF) have been developed in large...

FDA approves ADDERALL XR to treat ADHD in adults.
September 6, 2004... 2004 SEP 6 - (NewsRx.com & NewsRx.net) -- Shire Pharmaceuticals Group, plc, announced that the U.S. Food and Drug Administration (FDA) has approved ADDERALL XR (mixed salts of a single-entity amphetamine) as a once-daily treatment for adults...

Contract awarded to develop vaccine against H9N2 avian influenza.
September 6, 2004... 2004 SEP 6 - (NewsRx.com & NewsRx.net) -- The National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. National Institutes of Health (NIH), has awarded a contract to Chiron Corp. of Emeryville, California, for the...

S. dysenteriae 1 isolates derived from clone from single phage-integration event.
September 6, 2004... 2004 SEP 6 - (NewsRx.com & NewsRx.net) -- Shigella dysenteriae 1 isolates are derived from a clone resulting from a single phage-integration event. "The Shiga toxin (Stx) region of Shigella dysenteriae 1 lies on a defective prophage...

Benign prostatic hyperplasia clinical trial sties selected.
September 6, 2004... 2004 SEP 6 - (NewsRx.com & NewsRx.net) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) announced that most of the United States centers have been selected for the multicenter prostate Phase 2 study of NX-1207, the company's investigational...

"Hold-and-flush" method improves fluid chromatography fraction collection.
September 6, 2004... 2004 SEP 6 - (NewsRx.com & NewsRx.net) -- A novel "hold-and-flush" technique can improve collection of fluid chromatography fractions. "In supercritical fluid chromatography, the partial phase separation that occurs in the dead volume...

microRNAs quantitated using a modified Invader assay.
September 6, 2004... 2004 SEP 6 - (NewsRx.com & NewsRx.net) -- microRNAs were quantitated using a modified Invader assay. According to a study from the United States, "The short lengths of microRNAs (miRNAs) present a significant challenge for detection and...

Marijuana ingredient inhibits pathway required for brain tumor blood vessels.
September 6, 2004... 2004 SEP 6 - (NewsRx.com & NewsRx.net) -- Cannabinoids, the active ingredients in marijuana, restrict the sprouting of blood vessels to brain tumors by inhibiting the expression of genes needed for the production of vascular endothelial growth...

Patent application filed for TamoGel for treatment of benign breast disease.
September 6, 2004... 2004 SEP 6 - (NewsRx.com & NewsRx.net) -- Ascend Therapeutics has filed a patent application for both the pharmaceutical composition of TamoGel (4-hydroxytamoxifen gel) and the gel's use for the treatment of benign breast disease. The...

Pharmaceutical firm wins $13.1M biodefense research contract.
September 6, 2004... 2004 SEP 6 - (NewsRx.com & NewsRx.net) -- Caprion Pharmaceuticals, Inc., has been awarded a U.S. $13.1 million contract by the U.S. National Institute of Allergy and Infectious Diseases (NIAID), a part of the National Institutes of Health, to...

Antioxidant maker reports loss of $0.81 per share.
September 6, 2004... 2004 SEP 6 - (NewsRx.com & NewsRx.net) -- Aeolus Pharmaceuticals, Inc., (AOLS) announced the financial results for its third quarter of fiscal 2004, the 3-month period ended June 30, 2004. The company also reviewed recent events regarding...

Biopharmaceutical company announces 32% revenue increase for second quarter 2004.
September 6, 2004... 2004 SEP 6 - (NewsRx.com & NewsRx.net) -- Novavax, Inc., (NASDAQ:NVAX) announced its financial results for the second quarter ended June 30, 2004. Total revenues for the second quarter rose 32% to $3.0 million compared to second quarter...

Biopharmaceutical company reports improved first quarter financial results.
September 6, 2004... 2004 SEP 6 - (NewsRx.com & NewsRx.net) -- Repligen Corporation (NASDAQ:RGEN) reported results for the first quarter of fiscal year 2005 ended June 30, 2004. Total revenue for the quarter was $2,809,000 compared to total revenue of...

Chemical company to raise prices for hydrogen peroxide.
September 6, 2004... 2004 SEP 6 - (NewsRx.com & NewsRx.net) -- Solvay Chemicals Inc. will increase off-list prices for all grades of hydrogen peroxide. Prices will increase $0.05 per pound in the U.S. and $150 per metric ton in Canada for 100% basis hydrogen...

Cor Equity Holdings completes public spin-off.
September 6, 2004... 2004 SEP 6 - (NewsRx.com & NewsRx.net) -- Cor Equity Holdings, Inc.. (CEQH), announced that it has successfully completed the spin-off of its subsidiary, Medical Home Products, Inc. The trading symbol for the new public entity is MHPD. ...

Drug delivery developer reports quarterly finances, clinical pipeline update.
September 6, 2004... 2004 SEP 6 - (NewsRx.com & NewsRx.net) -- Acusphere, Inc., (ACUS) reported financial results for the second quarter ended June 30, 2004, and commented on its operational progress. The company's financial results for the second quarter of...

Fuzeon maker reports strong Q4 and year-end results.
September 6, 2004... 2004 SEP 6 - (NewsRx.com & NewsRx.net) -- Chronimed, Inc., (CHMD) reported record revenue and earnings for the fourth quarter and year ended July 2, 2004. Total reported company revenue for the 14-week quarter ending July 2, 2004 was a...

Genta announces second-quarter 2004 financial results.
September 6, 2004... 2004 SEP 6 - (NewsRx.com & NewsRx.net) -- Genta, Inc., (GNTA) announced financial results for the second quarter ended June 30, 2004. The company reported revenues of $1.6 million for the quarter, and a net loss of $29.2 million or $0.37...

Healthcare IT firm reports guidance in range of $29-31M.
September 6, 2004... 2004 SEP 6 - (NewsRx.com & NewsRx.net) -- Bio-Imaging Technologies, Inc., (BITI), announced its financial results for the second ended June 30, 2004. Mark L. Weinstein, president and CEO of Bio-Imaging, said, "We are pleased that during he...

MS drug maker reports loss of $0.02 per share.
September 6, 2004... 2004 SEP 6 - (NewsRx.com & NewsRx.net) -- AutoImmune, Inc., (AIMM) reported a net loss of $0.30 million, or $0.02 per share basic and diluted, for the 3 months ended June 30, 2004, compared with net loss of $0.14 million, or $0.01 per share...

Pharma company reports successful results for the second quarter 2004.
September 6, 2004... 2004 SEP 6 - (NewsRx.com & NewsRx.net) -- NitroMed, Inc., (NASDAQ: NTMD) reported financial results for the second quarter ended June 30, 2004. The company also reported on recent corporate achievements, including the early halt to its...

Pharmaceutical company announces 41% second quarter revenue increase.
September 6, 2004... 2004 SEP 6 - (NewsRx.com & NewsRx.net) -- Questcor Pharmaceuticals, Inc., (AMEX:QSC) announced financial results for the quarter and 6 months ended June 30, 2004. Total revenue for the second quarter of 2004 was $4,090,000, up 41% from...

Pharmaceutical company launches share buy-back program.
September 6, 2004... 2004 SEP 6 - (NewsRx.com & NewsRx.net) -- Novartis AG (NYSE: NVS) announced that its board of directors has decided to launch a new share repurchase program for up to CHF 3 billion following the completion of a program initiated in 2002. ...

Pharmaceutical company reports fiscal year 2004 earnings.
September 6, 2004... 2004 SEP 6 - (NewsRx.com & NewsRx.net) -- The Perrigo Company (NASDAQ:PRGO) announced results for the full year and fourth quarter ended June 26, 2004. Sales for the 12 months ended June 26, 2004, were $898.2 million, compared with $834.1...

Pharmaceutical company reports on events in fiscal year 2004.
September 6, 2004... 2004 SEP 6 - (NewsRx.com & NewsRx.net) -- Lannett Company, Inc., (LCI) reported on events that have occurred during its fiscal year ended June 30, 2004. On February 6, 2004, William Farber, the company's majority shareholder, entered into...

Biopharmaceutical company receives delisting notice from Nasdaq.
September 6, 2004... 2004 SEP 6 - (NewsRx.com & NewsRx.net) -- Citing the postponement of the filing of VaxGen's financial statements for the fiscal quarters ended March 30 and June 30, 2004, which is due to the company implementing what it believes is a more...

CRO announces $2.0 million of new business contracts.
September 6, 2004... 2004 SEP 6 - (NewsRx.com & NewsRx.net) -- Commonwealth Biotechnologies, Inc., (CBTE) (CBI), a contract research organization (CRO), announced new contract work in two of its core business areas, biodefense and clinical lab trial support. ...

CRO awarded $9.7 million of new business with major biopharmaceutical company.
September 6, 2004... 2004 SEP 6 - (NewsRx.com & NewsRx.net) -- Covalent Group, Inc., (CVGR) announced that it was awarded $9.7 million of new business to provide full-service management and operational support of a clinical research program that includes an...

Curative Health Services renews contract for Synagis.
September 6, 2004... 2004 SEP 6 - (NewsRx.com & NewsRx.net) -- Curative Health Services, Inc., (CURE), has renewed its contract with MedImmune, Inc., for its Critical Care Systems branch network and its other affiliated pharmacies to act as one of a select group of...

Global research organization announces Center for Pricing and Reimbursement.
September 6, 2004... 2004 SEP 6 - (NewsRx.com & NewsRx.net) -- MEDTAP International, Inc., announced PharmAnalysis Group, Inc., a provider of reimbursement planning for the pharmaceutical, biotechnology, medical device, and diagnostics industries, as MEDTAP's new...

Jenapharm's therapeutics business sold to Dermapharm AG.
September 6, 2004... 2004 SEP 6 - (NewsRx.com & NewsRx.net) -- Schering AG (SHR) announced that its German subsidiary, Jenapharm GmbH & Co. KG, Jena, has agreed to the sale of its therapeutics business to mibe Vertriebsgesellschaft mbH (i.G.), Jena, a subsidiary of...

Laredo Investment Corp announces name change.
September 6, 2004... 2004 SEP 6 - (NewsRx.com & NewsRx.net) -- Laredo Investment Corp (LRDI) has changed its company name to GFR Pharmaceuticals Inc., and has a new trading symbol (GFRP). This name change was made to better reflect the relationship with its...

Oral drug delivery technology supply agreement executed for chewable products.
September 6, 2004... 2004 SEP 6 - (NewsRx.com & NewsRx.net) -- AXM Pharma, Inc., (AXJ) has executed an exclusive supply agreement for an oral drug delivery technology for chewable tablets, capsules, and lozenges from WN Pharmaceuticals Ltd. AXM Pharma acquired...

Pharmaceuticals company signs sales, marketing agreement with services provider.
September 6, 2004... 2004 SEP 6 - (NewsRx.com & NewsRx.net) -- Ventiv Health, Inc. (VTIV) announced that it has signed a sales and marketing agreement with Aventis Pharmaceuticals (AVE) that incorporates Ventiv's integrated services. Under the terms of the...

Pharmacy chain offers financing update.
September 6, 2004... 2004 SEP 6 - (NewsRx.com & NewsRx.net) -- Rite Aid Corporation (NYSE, PCX:RAD) announced that is has reached agreement with its lead banks, Citigroup Global Markets, Inc., and J.P. Morgan Securities, Inc., to replace its existing senior secured...

Systems biology company adds Bristol-Myers Squibb to customer base.
September 6, 2004... 2004 SEP 6 - (NewsRx.com & NewsRx.net) -- GeneGo, Inc., announced that Bristol-Myers Squibb (BMS) has licensed its MetaCore data mining suite that combines analytical tools, data content, and algorithms for understanding complex interconnected...

Pharmaceutical company reports second quarter, clinical development results.
September 6, 2004... 2004 SEP 6 - (NewsRx.com & NewsRx.net) -- Progenics Pharmaceuticals, Inc., (NASDAQ: PGNX) announced its results of operations for the second quarter ended June 30, 2004, and first half of 2004. The company also provided an update of its...

Spin-off company announces second quarter 2004 financial results.
September 6, 2004... 2004 SEP 6 - (NewsRx.com & NewsRx.net) -- Pharmacopeia Drug Discovery, Inc., (NASDAQ:PCOP) announced results for the 3 and 6 months ended June 30, 2004. On April 30, 2004, the spin-off of Pharmacopeia Drug Discovery into an independent,...

BNO69 angiogenesis gene discovery published in journal.
September 6, 2004... 2004 SEP 6 - (NewsRx.com & NewsRx.net) -- Bionomics Limited announced that research conducted by Bionomics and its collaborators at the Hanson Centre of the Institute of Medical and Veterinary Science (IMVS) in Adelaide, Australia, relating to...

Collaboration to develop orally active chloride channel blocker cancer therapy.
September 6, 2004... 2004 SEP 6 - (NewsRx.com & NewsRx.net) -- TopoTarget A/S has entered into a collaboration with NeuroSearch (NEUR.CO) to develop the NeuroSearch compound Endovion (NS3728), an orally active chloride channel blocker for the treatment of cancer....

Pharma company reports financial results consistent with earlier guidance.
September 6, 2004... 2004 SEP 6 - (NewsRx.com & NewsRx.net) -- Onyx Pharmaceuticals, Inc., (NASDAQ:ONXX) reported a net loss of $13.1 million, or $0.38 per share, for the second quarter ended June 30, 2004, compared with a net loss of $11.4 million, or $0.48 per...

U.K. patient organizations recommends Glivec for inoperapeable tumors.
September 6, 2004... 2004 SEP 6 - (NewsRx.com & NewsRx.net) -- The National Institute for Clinical Excellence (NICE) concluded that Glivec (imatinib) should be prescribed in England and Wales, as a first-line option for all people with unresectable (inoperable)...

Non-CpG motif oligonucleotides for cancer vaccination developed.
September 6, 2004... 2004 SEP 6 - (NewsRx.com & NewsRx.net) -- Scientists have developed immunomodulatory six base-length non-CpG motif oligonucleotides for cancer vaccination. According to recent research from Canada, "We have previously described a novel...

Plasmid DNA in microparticles stimulates durable T cell responses.
September 6, 2004... 2004 SEP 6 - (NewsRx.com & NewsRx.net) -- Repeated immunization with plasmid DNA formulated in poly(lactide-co-glycolide) microparticles is well tolerated and stimulates durable T cell responses to the tumor-associated antigen cytochrome...

Biotechnology added to drug watch list, settles patent litigation, names CEO.
September 6, 2004... 2004 SEP 6 - (NewsRx.com & NewsRx.net) -- Prana Biotechnology Limited (NASDAQ:PRAN) announced that Forbes.com has once again added Prana to it's list of "neurological drugs to watch," highlighting the most promising experimental drugs to treat...

Pharmaceutical companies announce research extension of PDE4 collaboration.
September 6, 2004... 2004 SEP 6 - (NewsRx.com & NewsRx.net) -- Roche and Memory Pharmaceuticals Corp. (NASDAQ:MEMY) announced a 2-year extension of their PDE4 collaboration under their 2002 agreement. Under the extended agreement, Roche is committed to a...

Biosafety aspects of live oral Vibrio cholerae vaccine strain examined.
September 6, 2004... 2004 SEP 6 - (NewsRx.com & NewsRx.net) -- Researchers examine the biosafety aspects of the recombinant live oral Vibrio cholerae vaccine strain CVD 103-HgR in a recent issue of the journal Vaccine. "The development of live attenuated...

Annual meeting focused on high cholesterol guidelines and therapeutics.
September 6, 2004... 2004 SEP 6 - (NewsRx.com & NewsRx.net) -- Discussion about the science behind the recent changes to the National Cholesterol Education Program (NCEP) cholesterol-lowering guidelines and novel therapeutic approaches in the management of patients...

Collaboration set to discover biomarkers for COPD diagnostics, therapeutics.
September 6, 2004... 2004 SEP 6 - (NewsRx.com & NewsRx.net) -- GenData Research Corporation and Battelle have entered into a collaboration for the discovery, development, and commercialization of biomarkers for diagnostic and therapeutic applications in chronic...

Research shows pharmaceutical companies stay lean through outsourcing.
September 6, 2004... 2004 SEP 6 - (NewsRx.com & NewsRx.net) -- A study by Cutting Edge Information finds leading pharmaceutical companies no longer use vendors just to meet demands their teams and plants cannot handle - they seek to "buy in" complete processes and...

Companies form alliance to develop SAP solutions for pharma, biotech firms.
September 6, 2004... 2004 SEP 6 - (NewsRx.com & NewsRx.net) -- Capgemini U.S. LLC has teamed with SAP to develop a rapidly deployable, fixed-price offering specifically for middle market pharmaceutical and biotech companies. FastPharma is Capgemini's...

Agreement signed for fourth generation LHRH antagonist D-63153.
September 6, 2004... 2004 SEP 6 - (NewsRx.com & NewsRx.net) -- AEterna Zentaris, Inc., (AEZ; AEZS) announced that its German subsidiary Zentaris GmbH and Spectrum Pharmaceuticals, Inc., (SPPI) have entered into a licensing and collaboration agreement on a fourth...

Cisbio announces collaborations with reagent developers.
September 6, 2004... 2004 SEP 6 - (NewsRx.com & NewsRx.net) -- Cisbio international announced new business collaborations with two reagent suppliers, Cell Signaling Technology, Inc., (CST) and Upstate. These latest partnerships with well-established reagent...

Drug discovery alliance focused on cancer.
September 6, 2004... 2004 SEP 6 - (NewsRx.com & NewsRx.net) -- Array BioPharma, Inc., (ARRY) and QLT, Inc., (QLTI; QLT) announced the initiation of a drug discovery collaboration to create a series of small molecule therapeutics aimed at important cancer targets...

Late-stage development program for inhaled insulin to proceed.
September 6, 2004... 2004 SEP 6 - (NewsRx.com & NewsRx.net) -- Alkermes, Inc., (ALKS) announced that Eli Lilly and Company has made a positive product decision and will proceed with significant investment for the further development of an inhaled formulation of...

Licensing agreement signed for gene expression technology.
September 6, 2004... 2004 SEP 6 - (NewsRx.com & NewsRx.net) -- Artemis Pharmaceuticals GmbH, Cologne, and Regeneron Pharmaceuticals, Inc., (REGN), Tarrytown, New York, have signed an agreement under which Artemis grants to Regeneron a non-exclusive sublicense to...

Neugene antisense deal inked with USAMRIID on biodefense agents.
September 6, 2004... 2004 SEP 6 - (NewsRx.com & NewsRx.net) -- AVI BioPharma, Inc., (AVII) announced it has signed a Cooperative Research and Development Agreement (CRADA) with the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID). The...

Pharmaceutical company achieves $3M milestone under Merck collaboration.
September 6, 2004... 2004 SEP 6 - (NewsRx.com & NewsRx.net) -- Arena Pharmaceuticals, Inc., (ARNA) announced the achievement of a $3 million milestone from Merck & Co., Inc., for assay development under their cardiovascular collaboration. In October 2002,...

Rights granted to generic Actiq cancer pain treatments.
September 6, 2004... 2004 SEP 6 - (NewsRx.com & NewsRx.net) -- Barr Pharmaceuticals, Inc., (BRL) announced that its subsidiary, Barr Laboratories, Inc., has entered into an agreement with Cephalon, Inc., that will provide the company with a license to manufacture...

University of S. Florida to collaborate on drug performance co-crystal research.
September 6, 2004... 2004 SEP 6 - (NewsRx.com & NewsRx.net) -- TransForm Pharmaceuticals, Inc. (TransForm) announced a major collaborative effort with the University of South Florida (USF) in Tampa, Florida, in the design and discovery of pharmaceutical co-crystal...

Stool-based DNA testing reviewed.
September 6, 2004... 2004 SEP 6 - (NewsRx.com & NewsRx.net) -- The utility of stool-based DNA testing for colorectal cancer has been reviewed. "Despite a variety of screening strategies and recent trends showing death rate stabilization, colorectal cancer still...

Continuing medical education group restructures.
September 6, 2004... 2004 SEP 6 - (NewsRx.com & NewsRx.net) -- The three women who founded Phoenix Marketing Solutions 2 years ago - and DiMedix 6 months ago - have restructured their operation by adding Phoenix Group Holdings, an umbrella organization that will...

Online CME resource for primary care physicians launched.
September 6, 2004... 2004 SEP 6 - (NewsRx.com & NewsRx.net) -- Beginning in September 2004 primary care practitioners will be able to earn Continuing Medical Education credits on the latest topics in primary care at no cost when the nation's leading CME provider...

Phase I trial initiated for thrombin inhibitor, ARC183.
September 6, 2004... 2004 SEP 6 - (NewsRx.com & NewsRx.net) -- Archemix Corp. and Nuvelo, Inc., (NUVO) announced the commencement of dosing in a phase I clinical trial of ARC183, an anti-thrombin aptamer that is being developed as an anticoagulant/anti-thrombotic...

Adacolumn Apheresis System for Crohn disease initiated.
September 6, 2004... 2004 SEP 6 - (NewsRx.com & NewsRx.net) -- Following U.S. Food and Drug Administration (FDA) review of an IDE submitted by Otsuka America Pharmaceutical, Inc., a pivotal study of the Adacolumn Apheresis System for treatment of Crohn disease is...

IND filed for clinical trial to study aerosol candidate in cystic fibrosis.
September 6, 2004... 2004 SEP 6 - (NewsRx.com & NewsRx.net) -- Mpex Pharmaceuticals, Inc., has filed an Investigational New Drug Application (IND) for a phase Ib clinical trial to study an aerosol drug candidate in patients with cystic fibrosis (CF). Candidate...

Cytokine flow cytometry analyzes T-cell responses to cytomegalovirus.
September 6, 2004... 2004 SEP 6 - (NewsRx.com & NewsRx.net) -- Cytokine flow cytometry analyzes T-cell responses to cytomegalovirus. "T-cell responses to human cytomegalovirus (CMV) are readily detected in chronically infected adults, and are thought to be...

Blue Cross Blue Shield of Missouri implements doctor notification program.
September 6, 2004... 2004 SEP 6 - (NewsRx.com & NewsRx.net) -- On March 22, 2004, the Food and Drug Administration (FDA) issued a Public Health Advisory regarding the possible worsening of depression and suicidal thoughts in adults and children taking...